Research Program: Hematologic Malignancies

血液肿瘤项目 该计划在血液肿瘤的目标是发展一个更好的理解和改善 这组疾病的治疗。主要有四个重点领域：（1）加深理解 血液恶性肿瘤的生物学基础;（2）利用这一认识，以发展更好的非 （3）发现新的方法来克服目前造血细胞移植的局限性 （4）利用这些发现改进造血细胞移植的实际应用 移植血液肿瘤项目目前有来自11个部门和3个部门的75名成员。 机构职能体系73名成员（97%）拥有同行评审的资金，或者是 临床试验血液肿瘤项目目前有2430万美元的赠款资金（直接美元）， 其中1690万美元是同行评审的，690万美元（40%）来自NCI。该计划共发表论文1218篇， 上一个补助期。27%为方案内，35%为方案间，19%为方案间 体制性的。2012年，148，040名美国人被诊断出患有血液恶性肿瘤，导致54，380人死亡。 死亡，使这些恶性肿瘤共同成为继肺癌之后的第二大癌症死亡原因 (160，340），并超过了结肠（51，690），乳腺（39，920），胰腺（37，390）和 前列腺癌（28，170）。我们项目以前的工作提高了我们对这一群体的理解。 疾病，特别是骨髓恶性肿瘤，导致新的方法来筛选遗传 异常、改善的疾病进展监测和新的治疗方法。我们的研究结果 也使人们更好地理解了造血细胞移植问题背后的科学 并提供了克服这些问题中的一些问题从而提高治愈率的方法。议员 该计划还监督了一个非常繁忙的忙碌临床服务，仅在2013年就照顾了802名新患者，其中466人 (58%）在临床试验中接受治疗。

Hematologic Malignancies Program The goal of the Program in Hematologic Malignancies is to develop a better understanding and improved treatments for this group of diseases. Four areas of focus predominate: (1) Developing a deeper understanding of the biologic basis of hematologic malignancies; (2) Using this understanding to develop better non- transplant therapies; (3) Discovering novel methods to overcome the current limitations of hematopoietic cell transplantation; and (4) Using these discoveries to improve the actual practice of hematopoietic cell transplantation. The Hematologic Malignancies program currently has 75 members from 11 departments and 3 institutions. Seventy-three Members (97%) have peer-reviewed funding or are the Principal Investigator on a clinical trial. The Hematologic Malignancies program currently has $24.3M in grant funding (direct dollars) of which $16.9M is peer-reviewed and $6.9M (40%) is from NCI. The Program published a total of 1218 papers in the previous grant period. 27% were intra-programmatic, 35% were inter-programmatic and 19% were inter- institutional. In 2012, 148,040 Americans were diagnosed with a hematologic malignancy, resulting in 54,380 deaths, making these malignancies collectively the second leading cause of cancer death after lung cancer (160,340), and exceeding in aggregate the deaths from colon (51,690), breast (39,920) pancreas (37,390), and prostate cancer (28,170). Previous work from our program has improved our understanding of this group of diseases, particularly the myeloid malignancies, leading to new approaches to screening for genetic abnormalities, improved monitoring of disease progression and novel therapeutics. Results from our studies have also led to a better understanding of the science behind problems of hematopoietic cell transplantation and provided methods to overcome some of these problems leading to improved cure rates. Members of this program also oversee a very busy clinical service, caring for 802 new patients in 2013 alone, of which 466 (58%) were treated on clinical trials.